Online first
Review article
Published online: 2025-02-14
Bispecific antibodies in multiple myeloma
1, 2
Abstract
The outcomes of multiple myeloma (MM) patients have significantly improved over recent years due to the introduction
of novel therapies. Nevertheless, the disease remains incurable and the prognoses of patients with relapses are
poor. T-cell redirecting bispecific antibodies (BsAbs) have recently demonstrated efficacy in patients with relapsed or
refractory disease. Teclistamab, elranatamab, and talquetamab are novel BsAbs approved as monotherapies for the
treatment of relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors, immunomodulatory
agents, and anti-CD38 antibodies. Their efficacy and safety have been demonstrated in phase II multicenter trials.
Additionally, several other BsAbs are currently being investigated in clinical studies. Ongoing research is focused on
expanding the application of BsAbs in MM, including their incorporation into earlier lines of treatment and their use in
combination with other anti-myeloma agents. In this review, we discuss the tolerability and efficacy of three approved
BsAbs i.e. teclistamab, elrantamab and talquetamab.
Keywords: bispecific antibodiestherapymultiple myelomarefractoryrelapsed
References
- Ludwig H, Novis Durie S, Meckl A, et al. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020; 25(9): e1406–e1413.
- World Health Organization, Global Cancer Observatory, GLOBOCAN 2022: Leukemia Fact Sheet. 2022. Available from:. https://gco.iarc.who.int/media/globocan/factsheets/cancers/36-leukaemia-fact-sheet.pdf..
- Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024; 99(9): 1802–1824.
- Côté J, LeBlanc R, Mian H, et al. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer J. 2023; 13(1): 137.
- Rodzaj M, Morawska-Krekora A, Razny M, et al. Survival in patients with multiple myeloma: a real-life single-center study. Acta Haematol Pol. 2022; 53(3): 201–206.
- Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023; 30(2): 2322–2347.
- Jurczyszyn A, Charliński G, Vesole D. Supportive care in multiple myeloma. Acta Haematol Pol. 2022; 53(4): 227–240.
- Kubicki T, Adamska M, Żyłka K, et al. Therapy-related myeloid malignancies in patients with multiple myeloma. Acta Haematol Pol. 2024; 55(4): 192–201.
- Grząśko N, et al. Treatment of relapsed and refractory multiple myeloma. Acta Hematol Pol. 2025.
- MacEwan JP, Majer I, Chou JW, et al. The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma. Ther Adv Hematol. 2021; 12: 20406207211027463.
- Holstein SA, Grant SJ, Wildes TM. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future. J Clin Oncol. 2023; 41(27): 4416–4429.
- Rodriguez-Otero P, Usmani S, Cohen AD, et al. International Myeloma Working Group. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024; 25(5): e205–e216.
- Fadilah M, Sultan H, El-Gammal MA, et al. Prognostic value of B-cell maturation antigen, CD56 expression and neutrophil lymphocyte ratio in patients with multiple myeloma. Acta Haematol Pol. 2022.
- Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020; 34(4): 985–1005.
- Rodriguez-Otero P, van de Donk NW, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024; 14(1): 24.
- Tapia-Galisteo A, Álvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023; 16(1): 83.
- Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017; 31(8): 1743–1751.
- Moreau P, Garfall AL, van de Donk NW, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6): 495–505.
- Garfall A, Nooka A, Donk Nv, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 2024; 42(16_suppl): 7540–7540.
- Touzeau C, Krishnan AY, Moreau P, et al. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024; 144(23): 2375–2388.
- Qureshi Z, Jamil A, Altaf F, et al. Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis. Ann Hematol. 2024; 103(12): 4901–4912.
- Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023; 29(9): 2259–2267.
- Tomasson M, Iida S, Niesvizky R, et al. Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 2023; 142(Supplement 1): 3385–3385.
- Tomasson MH, Iida S, Niesvizky R, et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. Hemasphere. 2024; 8(7): e136.
- Mohty M, Bahlis NJ, Nooka AK, et al. Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. Br J Haematol. 2024; 204(5): 1801–1810.
- Schinke C, Touzeau C, Minnema M, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 2023; 41(16_suppl): 8036–8036.
- Rasche L, Schinke C, Touzeau C, et al. MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma and Leukemia. 2024; 24: S561–S562.
- Smith EJ, Olson K, Haber LJ, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015; 5: 17943.
- Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024; 42(22): 2702–2712.
- Regeneron. Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma. 2024; Available from: https://investor. regeneron com/news-releases/news-release-details/updated-linvoseltamab-data-showcase.
- D'Souza A, Shah N, Rodriguez C, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022; 40(31): 3576–3586.
- Sun M, Qiu L, Wei Y, et al. Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 2023; 41(16_suppl): 8038–8038.
- Trudel S, Cohen A, Krishnan A, et al. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. Blood. 2021; 138(Supplement 1): 157–157.
- Kazandjian D, Quach H, Sia H, et al. Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM). Blood. 2023; 142(Supplement 1): 4707–4707.
- Konishi T, Ochi T, Maruta M, et al. Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE. Blood. 2023; 142(21): 1789–1805.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019; 25(4): 625–638.
- Rodriguez-Otero P, Usmani S, Cohen AD, et al. International Myeloma Working Group. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024; 25(5): e205–e216.
- Pan D, Richter J. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma. Curr Hematol Malig Rep. 2024; 19(6): 237–245.
- Marin E, Scott S, Maples K, et al. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood. 2023; 142(Supplement 1): 2008–2008.
- Trudel S, Bahlis N, Spencer A, et al. Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity. Blood. 2022; 140(Supplement 1): 1363–1365.
- Kowalski A, Lykon J, Diamond B, et al. Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience. Blood. 2023; 142(Supplement 1): 4709–4709.
- Lancman G, Parsa K, Kotlarz K, et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023; 4(6): 440–451.
- Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023; 7(13): 3069–3074.
- Reynolds G, Cliff ER, Mohyuddin GR, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023; 7(19): 5898–5903.
- Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol. 2004; 122(3): 565–573.
- Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022; 387(24): 2232–2244.
- Chari A, Oriol A, Krishnan A, et al. Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study. Blood. 2023; 142(Supplement 1): 1010–1010.
- Nooka AK, Rodriguez C, Mateos MV, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024; 130(6): 886–900.
- Usmani S, Karlin L, Benboubker L, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. Journal of Clinical Oncology. 2023; 41(16_suppl): 8034–8034.
- Sandahl TB, Soefje SA, Fonseca R, et al. Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration. JCO Oncol Pract. 2024 [Epub ahead of print]: OP2400489.
- Tabbara N, Singel M, Allen N, et al. Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 2024; 42(16_suppl): 11146–11146.
